CRVO.US CervoMed Inc.

Healthcare Biotechnology USA Stocks
1.69 USD
Close of Nov 13, 2026
1.27 10.00
Market cap
USD 25.6M
P/E
-
P/B
1.60x
ROE
-157.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CRVO.US undervalued?

Graham number

The Graham number of CervoMed Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CervoMed Inc. fundamental analysis

No fundamental analysis for CervoMed Inc. yet.

CervoMed Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CervoMed Inc.

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical develop…

Full company profile